Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3926
Heron Therapeutics
HRTX
$64.7M
| $394K | ﹤0.01% |
303,209
+23,852
| +9% | +$29.4K |
|
|
XOMA
3927
DELISTED
Xoma
XOMA
| $394K | ﹤0.01% |
14,822
+1,598
| +12% | +$51.4K |
|
|
ACRE
3928
Ares Commercial Real Estate
ACRE
$261M
| $394K | ﹤0.01% |
82,334
+7,891
| +11% | +$38.4K |
|
3929
PUT
PagerDuty
PD
$876M
| $393K | ﹤0.01% |
+30,000
| New | +$438K |
|
3930
Orchestra BioMed
OBIO
$266M
| $392K | ﹤0.01% |
94,517
+94,516
| +9,451,600% | +$381K |
|
3931
Goldman Sachs Innovate Equity ETF
GINN
$214M
| $392K | ﹤0.01% |
+5,362
| New | +$398K |
|
3932
KORU Medical Systems
KRMD
$152M
| $392K | ﹤0.01% |
67,442
+5,457
| +9% | +$26.1K |
|
3933
Candel Therapeutics
CADL
$783M
| $392K | ﹤0.01% |
69,344
+9,749
| +16% | +$52.4K |
|
3934
Five Point Holdings
FPH
$372M
| $392K | ﹤0.01% |
70,087
| – | – |
|
3935
Parke Bancorp
PKBK
$409M
| $391K | ﹤0.01% |
15,631
-3,202
| -17% | -$72.1K |
|
3936
iShares ESG Aware MSCI EAFE ETF
ESGD
$12.3B
| $391K | ﹤0.01% |
+4,111
| New | +$388K |
|
3937
Microvision
MVIS
$111M
| $390K | ﹤0.01% |
31,371
+7,935
| +34% | +$127K |
|
3938
Bel Fuse Inc Class A
BELFA
$3.43B
| $389K | ﹤0.01% |
2,562
+281
| +12% | +$37.7K |
|
3939
Medallion Financial
MFIN
$257M
| $388K | ﹤0.01% |
37,672
+1,834
| +5% | +$18.4K |
|
3940
James River Group Holdings
JRVR
$199M
| $388K | ﹤0.01% |
60,941
+3,528
| +6% | +$20.3K |
|
3941
Johnson Outdoors
JOUT
$499M
| $387K | ﹤0.01% |
9,117
+1,612
| +21% | +$66.7K |
|
3942
Safe Bulkers
SB
$760M
| $387K | ﹤0.01% |
80,244
-7,113
| -8% | -$33.7K |
|
3943
Aviat Networks
AVNW
$282M
| $387K | ﹤0.01% |
18,078
+1,779
| +11% | +$39.7K |
|
3944
CALL
Regenxbio
RGNX
$720M
| $386K | ﹤0.01% |
26,800
+5,400
| +25% | +$67.3K |
|
|
3945
PUT
Regenxbio
RGNX
$720M
| $386K | ﹤0.01% |
26,800
+5,400
| +25% | +$67.3K |
|
3946
Rekor Systems
REKR
$94M
| $385K | ﹤0.01% |
+279,175
| New | +$570K |
|
3947
CALL
Aurora
AUR
$13.5B
| $384K | ﹤0.01% |
100,000
-400,000
| -80% | -$1.83M |
|
|
URG
3948
Ur-Energy
URG
$537M
| $384K | ﹤0.01% |
276,000
+254,218
| +1,167% | +$376K |
|
3949
Lightpath Technologies
LPTH
$862M
| $383K | ﹤0.01% |
+35,469
| New | +$287K |
|
3950
Norwood Financial Corp
NWFL
$376M
| $383K | ﹤0.01% |
13,656
+1,518
| +13% | +$41.4K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.